Study of PD-1 Inhibition With Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy

Condition:   Invasive Breast Cancer Interventions:   Drug: Cemiplimab;   Drug: Paclitaxel;   Drug: Carboplatin (not mandatory);   Drug: Doxorubicin;   Drug: Cyclophosphamide Sponsor:   Medical College of Wisconsin Not yet recruiting

Source: ClinicalTrials.gov - January 28, 2020 Category: Research Source Type: clinical trials